A Phase 2 interventional study of Abemaciclib in Breast Cancer, Non-small Cell Lung Cancer and Melanoma, sponsored by Eli Lilly and Company. Completed at 44 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.
Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 22nd largest by enrollment, is one of 2 that started in 2015, is one of 27 in phase 2, and was the 5th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Japanese Foundation for Cancer Research · Sites in Japan
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 29 · Phase 3 11 · Phase 4 8
First in 2014; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 55 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 55 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 34th largest by enrollment of the 80 interventional ones that give a count, is one of 2 that started in 2015, is one of 41 in phase 2, and was the 52nd registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
6 of the studies testing abemaciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06341621Phase 3Fudan UniversityChemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib | 2027-02-25 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT06207734Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDiscontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | 2027-01-10 |
| NCT04614194University of Texas Southwestern Medical CenterSingle Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | 2027-04-15 |
| NCT04305834City of Hope Medical CenterAbemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 55 studies testing abemaciclib in Breast Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET). Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib
Administered orally
Also known as: LY2835219
This study also gives Trastuzumab. No intervention listed here names it: that was found by reading the record.
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)
OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 millimeter (mm).
Time frame: Baseline to Objective Disease Progression (Up to 36 Months)
Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR)
Percentage of Participants with BOIR was categorized as CR, PR, SD, PD or NE, as defined by RANO-BM, from baseline until the earliest of objective progression according to brain metastases response criteria or start of new anticancer therapy. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \<30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. NE is absent (no abnormality; normal), or non-evaluable (NE).
Time frame: Baseline to Earliest Objective Progression or Start of New Anticancer Therapy (Up to 36 Months)
Duration of CR or PR: Duration of Intracranial Response (DOIR)
DOIR is measured from the date of first evidence of a confirmed response (CR or PR), as defined by RANO-BM, to the date objective progression or death from any cause. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Participants who have neither progressed nor died were censored on the day of their last radiographic tumor assessment or on the date of response. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. DOIR was summarized using Kaplan-Meier estimates.
Time frame: Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Up to 36 Months)
Percentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)
Percentage of participants with BOIR of CR, PR, or SD: IDCR, as defined by RANO-BM is reported. CR is measurable target lesions, the disappearance of all central nervous system CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. SD is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.
Time frame: Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)
Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)
ICBR is the percentage of participants with BOIR of CR, PR, or SD with duration of SD for at least 6 months, as defined by RANO-BM. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \<30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.
Time frame: Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)
Overall Survival (OS)
OS was measured from baseline to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for a particular analysis, OS was censored for that analysis at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, tumor assessment date, visit date, and last known alive date). OS was summarized using Kaplan-Meier estimates.
Time frame: Baseline to the Date of Death from Any Cause (Up to 5 Years)
Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR)
The percentage of participants with a best response of CR or PR objective response rate is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.
Time frame: Baseline to Disease Progression (Up to 36 Months)
Percentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR)
Disease control rate (DCR) (CR+ PR+ SD) per RECIST v1.1. is defined as the percentage of participants with best overall response of CR, PR, or SD. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.
Time frame: Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)
Progression Free Survival (PFS) Bi-compartmental
PFS was measured from baseline to objective progression (intracranial or extracranial) as defined by (RANO-BM.) or death from any cause. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. PFS was summarized using Kaplan-Meier estimates.
Time frame: Baseline to Objective Disease Progression or Death from Any Cause (Up to 36 Months)
Change From Baseline in Neurologic Symptoms on the MD Anderson Inventory-Brain Tumor (MDASI-BT) Subscale
The MDASI-BT is an instrument to assess multi-symptoms in participants with brain tumor metastases (including those with brain metastases secondary to breast cancer). The MDASI-BT of participants with a change from baseline is reported as mean core symptoms, mean brain tumor symptoms, and symptom groupings (mean focal neurologic deficit, mean generalized/disease status symptoms, and mean gastrointestinal symptoms). The mean of all symptom subscale items was calculated where 0 equals "not present" and 10 equals "as bad as you can imagine." A change from baseline with negative values indicate improvement, positive values indicate worsening.
Time frame: Baseline, Cycle 3 (Up to 63 Days)
Pharmacokinetics (PK): Steady State Minimum Concentration (Cmin) of Abemaciclib and Its Metabolites LSN2839567 (M2), LSN3106726 (M20), and LSN3106729 (M18)
A PK plasma sample was taken prior to abemaciclib dose to analyze the minimum concentrations of abemaciclib and its metabolites (Cmin) - Individual Cmin values were averaged if there were 3 or more available data points, otherwise individual data are reported.
Time frame: Parts A, B, D, E, F, Cycle 3, Day 1: Predose; Part C, Cycle 4, Day 1: Predose
| Milestone | Part A Abemaciclib: Hormone Receptor (HR+) HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part C Abemaciclib: Surgical Resection | Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC) | Part E Abemaciclib: Melanoma | Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma |
|---|---|---|---|---|---|---|
| Started | 27 | 58 | 9 | 28 | 23 | 17 |
| Received at least one dose of study drug | 27 | 58 | 9 | 28 | 23 | 17 |
| Completed | 23 | 38 | 6 | 24 | 19 | 12 |
| Not completed | 4 | 20 | 3 | 4 | 4 | 5 |
| Withdrew: Lost to follow-up | 1 | 7 | 0 | 0 | 1 | 2 |
| Withdrew: Sponsor decision | 0 | 8 | 0 | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 3 | 5 | 3 | 2 | 1 | 2 |
OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 millimeter (mm).
| percentage of participants | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) | 0 | 5.8 | 0 | 0 |
Percentage of Participants with BOIR was categorized as CR, PR, SD, PD or NE, as defined by RANO-BM, from baseline until the earliest of objective progression according to brain metastases response criteria or start of new anticancer therapy. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \<30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. NE is absent (no abnormality; normal), or non-evaluable (NE).
| percentage of participants | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Partial Response | 0 | 5.8 | 0 | 0 |
| Stable Disease | 52.2 | 65.4 | 43.5 | 31.8 |
| Progressive Disease | 47.8 | 28.8 | 56.5 | 68.2 |
| Not Evaluable | 0 | 0 | 0 | 0 |
DOIR is measured from the date of first evidence of a confirmed response (CR or PR), as defined by RANO-BM, to the date objective progression or death from any cause. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Participants who have neither progressed nor died were censored on the day of their last radiographic tumor assessment or on the date of response. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. DOIR was summarized using Kaplan-Meier estimates.
| Months | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Duration of CR or PR: Duration of Intracranial Response (DOIR) | — | 8.8 (3.0 to 14.3) | — | — |
Percentage of participants with BOIR of CR, PR, or SD: IDCR, as defined by RANO-BM is reported. CR is measurable target lesions, the disappearance of all central nervous system CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. SD is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.
| percentage of participants | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Percentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR) | 52.2 | 71.2 | 43.5 | 31.8 |
ICBR is the percentage of participants with BOIR of CR, PR, or SD with duration of SD for at least 6 months, as defined by RANO-BM. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \<30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.
| percentage of participants | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR) | 13.0 | 26.9 | 26.1 | 9.1 |
OS was measured from baseline to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for a particular analysis, OS was censored for that analysis at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, tumor assessment date, visit date, and last known alive date). OS was summarized using Kaplan-Meier estimates.
| months | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Overall Survival (OS) | 10.06 (4.21 to 14.30) | 13.38 (9.60 to 20.84) | 7.13 (3.65 to 9.37) | 2.93 (1.22 to 4.31) |
The percentage of participants with a best response of CR or PR objective response rate is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.
| percentage of participants | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR) | 0 | 1.7 | 3.6 | 0 |
Disease control rate (DCR) (CR+ PR+ SD) per RECIST v1.1. is defined as the percentage of participants with best overall response of CR, PR, or SD. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.
| percentage of participants | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Percentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR) | 40.7 | 51.7 | 39.3 | 26.1 |
PFS was measured from baseline to objective progression (intracranial or extracranial) as defined by (RANO-BM.) or death from any cause. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. PFS was summarized using Kaplan-Meier estimates.
| Months | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| Progression Free Survival (PFS) Bi-compartmental | 2.07 (1.35 to 3.32) | 4.41 (2.60 to 5.46) | 1.45 (1.35 to 2.76) | 1.22 (1.02 to 1.55) |
The MDASI-BT is an instrument to assess multi-symptoms in participants with brain tumor metastases (including those with brain metastases secondary to breast cancer). The MDASI-BT of participants with a change from baseline is reported as mean core symptoms, mean brain tumor symptoms, and symptom groupings (mean focal neurologic deficit, mean generalized/disease status symptoms, and mean gastrointestinal symptoms). The mean of all symptom subscale items was calculated where 0 equals "not present" and 10 equals "as bad as you can imagine." A change from baseline with negative values indicate improvement, positive values indicate worsening.
| units on a scale | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma |
|---|---|---|---|---|
| mean core symptom severity | -0.98 ± 0.86 | -0.17 ± 0.99 | -0.38 ± 1.19 | -0.53 ± 0.62 |
| mean brain tumor symptom severity | -0.47 ± 0.57 | -0.29 ± 1.05 | -0.10 ± 1.22 | 0.31 ± 1.11 |
| mean focal neurologic deficit symptom severity | -0.84 ± 0.92 | -0.36 ± 1.23 | -0.44 ± 0.58 | 0.54 ± 1.16 |
| mean generalized disease status | -0.47 ± 1.03 | 0 ± 1.39 | 0.28 ± 1.51 | 0.01 ± 0.89 |
| mean gastrointestinal symptom | -1.35 ± 2.11 | 0.40 ± 1.91 | 1.00 ± 1.46 | 0 ± 0.29 |
A PK plasma sample was taken prior to abemaciclib dose to analyze the minimum concentrations of abemaciclib and its metabolites (Cmin) - Individual Cmin values were averaged if there were 3 or more available data points, otherwise individual data are reported.
| nanogram/milliliter (ng/mL) | Part A 150 mg Abemaciclib: HR+, HER2+ Breast Cancer | Part B 200 mg Abemaciclib: HR+, HER2- Breast Cancer | Part C 200 mg Abemaciclib: Surgical Resection | Part D 200 mg Abemaciclib: NSCLC | Part E 200 mg Abemaciclib: Melanoma | Part F 200 mg Abemaciclib: HR+ Breast Cancer, NSCLC, Melanoma |
|---|---|---|---|---|---|---|
| Abemaciclib | 133 ± 13.4 | 120 ± 186 | NA ± NA | 306 ± 33.5 | NA ± NA | 142 ± 80.0 |
| LSN2839567 (M2) | 72.6 ± 8.23 | 77.3 ± 121 | NA ± NA | 100 ± 77.5 | NA ± NA | 68.5 ± 150 |
| LSN3106726 (M20) | 158 ± 25.0 | 133 ± 160 | NA ± NA | 203 ± 43.3 | NA ± NA | 122 ± 137 |
| LSN3106729 (M18) | 36.8 ± 39.3 | 42.4 ± 85.6 | NA ± NA | 28.9 ± 108 | NA ± NA | 27.0 ± 242 |
Collected over Up to 36 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Abemaciclib: HR+, HER2+ Breast Cancer | 23/27 (85.2%) | 6/27 (22.2%) | 23/27 (85.2%) |
| Part B Abemaciclib: HR+, HER2- Breast Cancer | 38/58 (65.5%) | 16/58 (27.6%) | 55/58 (94.8%) |
| Part C Abemaciclib: Surgical Resection | 6/9 (66.7%) | 3/9 (33.3%) | 8/9 (88.9%) |
| Part D Abemaciclib: NSCLC | 24/28 (85.7%) | 8/28 (28.6%) | 27/28 (96.4%) |
| Part E Abemaciclib: Melanoma | 19/23 (82.6%) | 4/23 (17.4%) | 16/23 (69.6%) |
| Part F: Abemaciclib HR+ Breast Cancer, NSCLC, or Melanoma | 12/17 (70.6%) | 7/17 (41.2%) | 16/17 (94.1%) |
| Event | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part C Abemaciclib: Surgical Resection | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma | Part F: Abemaciclib HR+ Breast Cancer, NSCLC, or Melanoma |
|---|---|---|---|---|---|---|
| SeizureNervous system disorders | 2/27 | 0/58 | 0/9 | 1/28 | 1/23 | 2/17 |
| PancreatitisGastrointestinal disorders | 0/27 | 0/58 | 1/9 | 0/28 | 0/23 | 0/17 |
| SepsisInfections and infestations | 0/27 | 1/58 | 1/9 | 0/28 | 0/23 | 0/17 |
| HypokalaemiaMetabolism and nutrition disorders | 0/27 | 0/58 | 1/9 | 0/28 | 0/23 | 1/17 |
| Lung infectionInfections and infestations | 0/27 | 1/58 | 0/9 | 3/28 | 0/23 | 1/17 |
| DehydrationMetabolism and nutrition disorders | 0/27 | 0/58 | 0/9 | 0/28 | 2/23 | 1/17 |
| DiarrhoeaGastrointestinal disorders | 2/27 | 2/58 | 0/9 | 0/28 | 0/23 | 0/17 |
| AnaemiaBlood and lymphatic system disorders | 0/27 | 0/58 | 0/9 | 0/28 | 0/23 | 1/17 |
| NauseaGastrointestinal disorders | 0/27 | 0/58 | 0/9 | 0/28 | 0/23 | 1/17 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/27 | 0/58 | 0/9 | 0/28 | 0/23 | 1/17 |
| Event | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part C Abemaciclib: Surgical Resection | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma | Part F: Abemaciclib HR+ Breast Cancer, NSCLC, or Melanoma |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 15/27 | 45/58 | 4/9 | 15/28 | 5/23 | 6/17 |
| Alanine aminotransferase increasedInvestigations | 3/27 | 4/58 | 6/9 | 2/28 | 2/23 | 2/17 |
| FatigueGeneral disorders | 9/27 | 28/58 | 2/9 | 11/28 | 4/23 | 9/17 |
| NauseaGastrointestinal disorders | 9/27 | 26/58 | 2/9 | 8/28 | 1/23 | 7/17 |
| AnaemiaBlood and lymphatic system disorders | 3/27 | 12/58 | 4/9 | 5/28 | 2/23 | 5/17 |
| LeukopeniaBlood and lymphatic system disorders | 2/27 | 7/58 | 4/9 | 4/28 | 3/23 | 3/17 |
| NeutropeniaBlood and lymphatic system disorders | 6/27 | 17/58 | 4/9 | 7/28 | 5/23 | 2/17 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/27 | 11/58 | 4/9 | 8/28 | 3/23 | 3/17 |
| HypocalcaemiaMetabolism and nutrition disorders | 2/27 | 0/58 | 4/9 | 0/28 | 0/23 | 3/17 |
| VomitingGastrointestinal disorders | 7/27 | 20/58 | 2/9 | 4/28 | 1/23 | 5/17 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part C Abemaciclib: Surgical Resection | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma | Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma | Total |
|---|---|---|---|---|---|---|---|
| Mean | 49.9 ± 10.9 | 54.1 ± 10.5 | 57.0 ± 17.9 | 58.4 ± 10.9 | 55.1 ± 14.4 | 50.1 ± 12.3 | 54.0 ± 12.1 |
| Sex: Female, Male(Participants) | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part C Abemaciclib: Surgical Resection | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma | Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma | Total |
|---|---|---|---|---|---|---|---|
| Female | 27 | 57 | 8 | 14 | 11 | 14 | 131 |
| Male | 0 | 1 | 1 | 14 | 12 | 3 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part C Abemaciclib: Surgical Resection | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma | Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 0 | 0 | 1 | 1 | 5 |
| Not Hispanic or Latino | 21 | 42 | 8 | 20 | 20 | 14 | 125 |
| Unknown or Not Reported | 6 | 13 | 1 | 8 | 2 | 2 | 32 |
| Race (NIH/OMB)(Participants) | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part C Abemaciclib: Surgical Resection | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma | Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 3 | 1 | 0 | 0 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 0 | 1 | 0 | 1 | 7 |
| White | 17 | 35 | 7 | 20 | 22 | 14 | 115 |
| More than one race | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 7 | 15 | 1 | 7 | 1 | 2 | 33 |
| Region of Enrollment(Participants) | Part A Abemaciclib: HR+, HER2+ Breast Cancer | Part B Abemaciclib: HR+, HER2- Breast Cancer | Part C Abemaciclib: Surgical Resection | Part D Abemaciclib: NSCLC | Part E Abemaciclib: Melanoma | Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma | Total |
|---|---|---|---|---|---|---|---|
| Canada | 0 | 1 | 0 | 0 | 0 | 2 | 3 |
| Austria | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Belgium | 4 | 8 | 0 | 3 | 3 | 0 | 18 |
| United States | 11 | 24 | 7 | 12 | 7 | 10 | 71 |
| Italy | 0 | 4 | 0 | 2 | 9 | 0 | 15 |
| Israel | 1 | 2 | 0 | 1 | 1 | 1 | 6 |
| Australia | 2 | 2 | 1 | 2 | 1 | 1 | 9 |
| France | 7 | 14 | 1 | 7 | 1 | 2 | 32 |
| Spain | 2 | 2 | 0 | 1 | 1 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2015 to primary completion in Nov 2018, 42 months.
Results were first posted in Dec 2019, 1 year 1 month after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 42 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib